Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DexCom, Inc.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC